Intravenous Human Albumin In Improving Pancreaticoduodenectomy Outcomes


National University of Malaysia (UKM)

Status and phase

Phase 2


Pancreatic Fistula
Delayed Gastric Emptying
Anastomotic Leak
Pancreatic Cancer


Drug: Human albumin

Study type


Funder types




Details and patient eligibility


Pancreaticoduodenectomy (PD), more commonly known as Whipple's surgery is the mainstay treatment for pancreatic head and periampullary cancer. Factors contributing to PD outcomes are broadly categorized to disease-related, patient-related and operative factors. Whereas an inexhaustible list of study exists on looking at reducing PD complication rates with respect to the above-mentioned factors, it was only recently that more attention has been given to the impact of perioperative and intraoperative fluid regimes on PD outcomes. This study takes interest in the impact of intraoperative fluid regimes on PD outcomes. The objective of this investigation is to compare the outcomes with the use of intraoperative intravenous human albumin versus standard intraoperative fluid regimes.

Full description

This is a randomized controlled trial being conducted at the Universiti Kebangsaan Malaysia Medical Center (UKMMC) with two arms; the control and treatment arms. The treatment arm will receive intravenous human albumin intraoperatively whilst the control arm will receive standard intraoperative fluid regimes. Primary endpoint will be overall complication rates whilst secondary endpoints are length of hospitalization, length of ICU care, duration of gastroparesis, pancreatic fistula rates, surgical site infection rates, duration of surgery and intraoperative bleeding. Beyond the intraoperative fluid regimes, postoperative care follows the standardised UKMMC Enhanced Recovery After Surgery (ERAS) protocols which saw an improvement in overall outcomes in patients who underwent pancreaticoduodenectomies (PD). Preoperative care will include nutrition optimisation, counselling, antimicrobial prophylaxis, perioperative glycemic control and near-zero fluid balance. Data collection will include: i. preoperative data: age, sex, ethnicity, BMI on admission, date of admission, comorbidities and the New York Heart Association (NYHA) functional status classification. Further information will include biochemical markers such as serum albumin albumin, white cell count (WCC), renal functions. ii. Intraoperative information: duration of surgery, estimated blood loss, pancreatic duct size, pancreatic texture, amount and type of fluid administered, fluid balances and type of anastomoses. iii. postoperative data: fluid balances and renal function of postoperative day 1 to 3, duration of ICU stay, readmission to ICU, length of hospital stay, duration to standard feeds, grading of pancreatic fistula (where relevant), surgical site infection, duration to removal of urinary catheter, cardiac complications, renal and pulmonary complications, deep vein thrombosis, re-operation, and mortality.


122 estimated patients




Accepts Healthy Volunteers

Inclusion criteria

  • All patients undergoing pancreaticoduodenectomy that can consent to the study

Exclusion criteria

  • Patients with known allergy to human albumin
  • Patients of American Society of Anaesthesiologist (ASA) physical status class 3 and above.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Single Blind

122 participants in 2 patient groups

Control Arm
No Intervention group
Standard intraoperative fluid regime
Treatment Arm
Experimental group
Intravenous human albumin 1g/kg at skin incision running at 100ml/hour
Drug: Human albumin

Trial contacts and locations



Central trial contact

Sarah I Liew; Ian Chik

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems